4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Keymed Biosciences Inc. (2162) operates in the Biotechnology industry and is headquartered in Chengdu, China with about 1,625 employees. Its market capitalization is roughly CNY 24 billion. In the fiscal year ended 2025-12-31, 2162 reported CNY 716M in revenue and (CNY 523M) in net income.
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 716M | CNY 428M | CNY 354M | CNY 100M | — |
| Gross Profit | CNY 628M | CNY 416M | CNY 317M | CNY 98M | — |
| Operating Income (EBIT) | (CNY 548M) | (CNY 586M) | (CNY 435M) | (CNY 478M) | — |
| Net Income | (CNY 523M) | (CNY 515M) | (CNY 359M) | (CNY 308M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 4.2B | CNY 3.8B | CNY 3.9B | CNY 3.9B | — |
| Total Liabilities | CNY 1.4B | CNY 1.3B | CNY 896M | CNY 593M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2162 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms